2022
Longitudinal alterations in mRNA expression of the BDNF neurotrophin signaling cascade in blood correlate with changes in depression scores in patients undergoing electroconvulsive therapy
Schurgers G, Walter S, Pishva E, Guloksuz S, Peerbooms O, Incio L, Arts B, Kenis G, Rutten B. Longitudinal alterations in mRNA expression of the BDNF neurotrophin signaling cascade in blood correlate with changes in depression scores in patients undergoing electroconvulsive therapy. European Neuropsychopharmacology 2022, 63: 60-70. PMID: 36067540, DOI: 10.1016/j.euroneuro.2022.07.183.Peer-Reviewed Original ResearchConceptsBrain-derived neurotrophic factorBDNF/TrkBExpression of BDNFSerum BDNF protein levelsBDNF protein levelsElectroconvulsive therapyDepression scoresMRNA expressionPeripheral bloodTreatment-resistant depressed patientsProtein levelsMechanism of actionAntidepressant effectsNeurotrophic factorDepressed patientsLongitudinal alterationsSevere depressionBlood correlatesEffective treatmentLongitudinal changesTrkBStudy periodNR3C1PatientsTherapyThe association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study
Fusar-Poli L, Pries LK, van Os J, Radhakrishnan R, Pençe AY, Erzin G, Delespaul P, Kenis G, Luykx JJ, Lin BD, Akdede B, Binbay T, Altınyazar V, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran EŞ, Kaymak SU, Mihaljevic MM, Andric-Petrovic S, Mirjanic T, Bernardo M, Mezquida G, Amoretti S, Bobes J, Saiz PA, García-Portilla MP, Sanjuan J, Aguilar EJ, Santos JL, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric NP, Atbaşoğlu C, Üçok A, Alptekin K, Saka MC, investigators G, Aguglia E, Arango C, Rutten BP, Guloksuz S. The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. European Neuropsychopharmacology 2022, 63: 47-59. PMID: 36055075, DOI: 10.1016/j.euroneuro.2022.08.003.Peer-Reviewed Original ResearchConceptsHealthy controlsCannabis useDegraded Facial Affect Recognition TaskPresent cross-sectional studyCross-sectional studyHigh genetic riskProgression of schizophreniaRegular cannabis useCognitive disturbancesRegular cannabisPsychosis riskPatientsSchizophreniaFacial emotion recognition performanceGenetic riskCannabisCurrent cannabisEUGEI studyLongitudinal studyAgeSiblingsAssociationRiskOnsetEffect relationship
2021
Impact of the first COVID-19 outbreak on mental health service utilisation at a Dutch mental health centre: retrospective observational study
Chow M, Noorthoorn E, Wierdsma A, van der Horst M, de Boer N, Guloksuz S, Luykx J. Impact of the first COVID-19 outbreak on mental health service utilisation at a Dutch mental health centre: retrospective observational study. BJPsych Open 2021, 7: e213. PMID: 34784994, PMCID: PMC8632375, DOI: 10.1192/bjo.2021.1049.Peer-Reviewed Original ResearchMental health service utilisationHealth service utilisationService utilisationFirst COVID-19 outbreakCare contactsPatient contactPsychotic disordersVideo consultationsCOVID-19 outbreakDiagnostic categoriesRetrospective observational studyMental healthcare deliveryMental health centersCOVID-19 pandemicDifferent diagnostic categoriesPre-pandemic periodRetrospective studyHealth centersObservational studyMental illnessPatientsHealthcare deliveryHealthcare institutesTelepsychiatryCOVID-19 lockdownRisk profiles for mental disorders
Gülöksüz S. Risk profiles for mental disorders. European Psychiatry 2021, 64: s71-s71. PMCID: PMC9471330, DOI: 10.1192/j.eurpsy.2021.220.Peer-Reviewed Original ResearchPsychiatric diagnosisSame psychiatric diagnosisDifferent psychiatric diagnosesSame treatment protocolClinical staging modelRisk profilingDiagnosis-specific treatmentsSame treatment planTreatment protocolTreatment responseMedical conditionsClinical practiceDiagnostic classification systemsTreatment planMental disordersStaging modelRisk profileDiscrete diagnostic categoriesPatientsDiagnostic categoriesClinical predictionDiagnosisEarly psychopathologyTraditional diagnostic boundariesPrognosticationAssociation of the kynurenine pathway metabolites with clinical, cognitive features and IL-1β levels in patients with schizophrenia spectrum disorder and their siblings
Noyan H, Erdağ E, Tüzün E, Yaylım İ, Küçükhüseyin Ö, Hakan M, Gülöksüz S, Rutten B, Saka M, Atbaşoğlu C, Alptekin K, van Os J, Üçok A. Association of the kynurenine pathway metabolites with clinical, cognitive features and IL-1β levels in patients with schizophrenia spectrum disorder and their siblings. Schizophrenia Research 2021, 229: 27-37. PMID: 33609988, DOI: 10.1016/j.schres.2021.01.014.Peer-Reviewed Original ResearchConceptsSchizophrenia spectrum disordersIL-1β levelsKYNA levelsHigher serum IL-1β levelsSerum IL-1β levelsHigher KYNA levelsTrp-Kyn pathwayKynurenic acid levelsSimilar clinical featuresPathophysiology of schizophreniaManifestations of schizophreniaKYN levelsSerum interleukinClinical featuresInflammatory cytokinesIL-1βClinical dataKynurenine pathwayTRP levelsSpectrum disorderControl groupAdvanced stageLow TrpPathway dysregulationPatientsAntipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: A meta-analysis
Bak M, Drukker M, Cortenraad S, Vandenberk E, Guloksuz S. Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: A meta-analysis. PLOS ONE 2021, 16: e0244944. PMID: 33596211, PMCID: PMC7888647, DOI: 10.1371/journal.pone.0244944.Peer-Reviewed Original ResearchConceptsAntipsychotic-naive patientsBody weight changesBody weight gainWeight gainPsychiatric diagnosisNaive patientsWeight changeAntipsychotic useBodyweight gainAntipsychotic-naive groupMore weight gainDiagnosis of schizophreniaAntipsychotic switchMost antipsychoticsShort followSwitch studyMetabolic disturbancesClinical trialsOutcome measuresAntipsychoticsPatientsBody weightNaive groupSwitch groupDiagnosis
2020
Phenome-wide and genome-wide analyses of quality of life in schizophrenia
Pazoki R, Lin B, van Eijk K, Schijven D, de Zwarte S, Alizadeh B, van Amelsvoort T, Bartels-Velthuis A, van Beveren N, Bruggeman R, Cahn W, de Haan L, Delespaul P, Luykx J, Myin-Germeys I, Kahn R, Schirmbeck F, Simons C, van Os J, van Winkel R, Guloksuz S, Luykx J. Phenome-wide and genome-wide analyses of quality of life in schizophrenia. BJPsych Open 2020, 7: e13. PMID: 33295273, PMCID: PMC7791571, DOI: 10.1192/bjo.2020.140.Peer-Reviewed Original ResearchPolygenic risk scoresRisk scoreClinical phenotypeNon-genetic contributing factorsMajor depressive disorderQuality of lifeDepressive disorderHealthy controlsVulnerable patientsStudy populationHypothesis-generating approachPatientsPsychotic disordersQoLSmall studyClinical interventionsSchizophreniaGenotypic determinantsScoresContributing factorDisordersPhenotypeAssociationEvidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway
van Os J, Pries L, Have M, de Graaf R, van Dorsselaer S, Delespaul P, Bak M, Kenis G, Lin B, Luykx J, Richards A, Akdede B, Binbay T, Altınyazar V, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran E, Kaymak S, Mihaljevic M, Petrovic S, Mirjanic T, Bernardo M, Mezquida G, Amoretti S, Bobes J, Saiz P, García-Portilla M, Sanjuan J, Aguilar E, Santos J, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric N, Atbaşoğlu C, Ucok A, Alptekin K, Saka M, Arango C, O'Donovan M, Rutten B, Guloksuz S. Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway. Psychological Medicine 2020, 52: 1910-1922. PMID: 33070791, DOI: 10.1017/s0033291720003748.Peer-Reviewed Original ResearchConceptsSchizophrenia spectrum disordersChildhood adversityRisk factorsNEMESIS-2Affective dysregulationNon-genetic risk factorsSignificant depressive symptomsSample of patientsRepresentative general population sampleGenetic risk factorsGeneral population sampleSchizophrenia polygenic riskPsychosis outcomesSpectrum disorderDepressive symptomsPRS-SZPolygenic riskDysregulationPatientsPopulation samplePsychosisAffective pathwayDisordersHallucinatory experiencesDelusional ideationMinor Physical Anomalies in Bipolar Disorder
İnce B, Altinoz M, Ayran A, Cansız A, Altinbaş K, Guloksuz S, Kurt E. Minor Physical Anomalies in Bipolar Disorder. Comprehensive Psychiatry 2020, 103: 152206. PMID: 33099105, DOI: 10.1016/j.comppsych.2020.152206.Peer-Reviewed Original ResearchConceptsBipolar disorderMinor physical anomaliesBD patientsHealthy subjectsHigh arched palatePhysical anomaliesAuricular anomaliesPsychiatric disordersCleft lipPathogenesis pathwaysPatientsMinor anomaliesDeletion syndromeDisordersSecond pharyngeal archesDorsal endPalateSchizophreniaRegression modelsAuriclePharyngeal archesFirst pharyngeal archArchNew endophenotypesSubjects
2019
Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene–environment interaction. The EUGEI study
van Os J, Pries L, Delespaul P, Kenis G, Luykx J, Lin B, Richards A, Akdede B, Binbay T, Altınyazar V, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran E, Kaymak S, Mihaljevic M, Petrovic S, Mirjanic T, Bernardo M, Cabrera B, Bobes J, Saiz P, García-Portilla M, Sanjuan J, Aguilar E, Santos J, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric N, Atbaşoğlu C, Ucok A, Alptekin K, Saka M, Arango C, O'Donovan M, Rutten B, Guloksuz S. Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene–environment interaction. The EUGEI study. Psychological Medicine 2019, 50: 1884-1897. PMID: 31414981, DOI: 10.1017/s003329171900196x.Peer-Reviewed Original ResearchConceptsPsychotic disordersPolygenic riskSchizophrenia polygenic riskGene-environment interactionsGenetic riskRelatives of patientsFirst-degree relativesPsychosis phenotypeAverage genetic riskIntermediate phenotypesHealthy siblingsCognitive intermediate phenotypesControl groupAnalysis of associationAverage riskPatientsPhenotypic factors associated with amisulpride‐induced weight gain in first‐episode psychosis patients (from the OPTiMiSE cohort)
Pandit R, Cianci D, Hark S, Rossum I, Ebdrup B, Broberg B, Garcia‐Portilla M, Bobes J, Vinkers C, Kahn R, Guloksuz S, Huitema A, Luykx J. Phenotypic factors associated with amisulpride‐induced weight gain in first‐episode psychosis patients (from the OPTiMiSE cohort). Acta Psychiatrica Scandinavica 2019, 140: 283-290. PMID: 31323113, PMCID: PMC6771865, DOI: 10.1111/acps.13074.Peer-Reviewed Original ResearchConceptsFirst-episode psychosis patientsPsychosis patientsWeight gainSchizophreniform disorderAntipsychotic-induced weight gainFirst-episode patientsManagement of schizophreniaLower baseline weightMultivariable regression modelsWeight-reducing strategiesOptimization of treatmentRegression modelsMajor depression disorderPhenotypic factorsAmisulpride treatmentBaseline weightEurope (Syst-Eur) trialMost antipsychoticsDepression disorderYoung subjectsBody weightPatientsBetter efficacyYounger ageAIWG
2015
Temperament characteristics in patients with panic disorder and their first-degree relatives
Altınbaş G, Altınbaş K, Gülöksüz S, Gülöksüz S, Aydemir Ö, Özgen G. Temperament characteristics in patients with panic disorder and their first-degree relatives. Comprehensive Psychiatry 2015, 60: 73-77. PMID: 25967357, DOI: 10.1016/j.comppsych.2015.03.008.Peer-Reviewed Original ResearchConceptsFirst-degree relativesHealthy controlsPanic disorderIrritable temperament scoresPanic Agoraphobia ScaleAnxious temperament scoresTemperament characteristicsTrait Anxiety InventoryClinical characteristicsPatient groupClinical conditionsSan Diego AutoquestionnairePatientsTemperament scoresTrait markerAgoraphobia ScaleAnxiety disordersProspective designDisordersStudy sampleHeritable anxiety disordersAnxiety InventoryTemperament EvaluationEducation levelIntermediate phenotypes
2014
Clinical Features of Night Eating Syndrome among Depressed Patients
Kucukgoncu S, Tek C, Bestepe E, Musket C, Guloksuz S. Clinical Features of Night Eating Syndrome among Depressed Patients. European Eating Disorders Review 2014, 22: 102-108. PMID: 24436087, DOI: 10.1002/erv.2280.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnxiety DisordersBody Mass IndexCircadian RhythmDepressionFeeding and Eating DisordersFeeding BehaviorFemaleHumansInterviews as TopicMaleMiddle AgedObesityPersonality InventoryPrevalencePsychiatric Status Rating ScalesQuality of LifeRegression AnalysisSocioeconomic FactorsStress, PsychologicalSurveys and QuestionnairesSyndromeYoung AdultConceptsPittsburgh Sleep Quality IndexBeck Depression InventoryBeck Anxiety InventoryClinical featuresDepressed patientsDepression InventoryNon-NE patientsNight eating syndromeSleep Quality IndexSample of patientsAnxiety InventorySeverity of anxietyNight Eating QuestionnaireSocio-demographic formSmoking statusDaytime dysfunctionSleep qualityDepressed outpatientsPatientsSyndromeEating QuestionnaireStudy sampleBMISignificant differencesDepression
2013
Metabolic syndrome prevalence in different affective temperament profiles in bipolar-I disorder
Altinbas K, Guloksuz S, Oral E. Metabolic syndrome prevalence in different affective temperament profiles in bipolar-I disorder. Brazilian Journal Of Psychiatry 2013, 35: 131-135. PMID: 23904017, DOI: 10.1590/1516-4446-2011-0746.Peer-Reviewed Original ResearchConceptsMetabolic syndrome prevalenceDevelopment of MetSInternational Diabetes FederationMetabolic syndrome markersMood Disorders UnitSan Diego-Autoquestionnaire versionProportion of MetSDepressive temperament scoresAffective temperament profilesMetS prevalenceDiabetes FederationSyndrome prevalenceDisorders unitBipolar patientsBrain structuresSocioeconomic statusTemperament EvaluationPatientsMetSPrevalenceTemperament profilesTemperament scoresTemperamental profilesMetS.Depressive Symptoms in Crohn's Disease: Relationship with Immune Activation and Tryptophan Availability
Guloksuz S, Wichers M, Kenis G, Russel M, Wauters A, Verkerk R, Arts B, van Os J. Depressive Symptoms in Crohn's Disease: Relationship with Immune Activation and Tryptophan Availability. PLOS ONE 2013, 8: e60435. PMID: 23544139, PMCID: PMC3609785, DOI: 10.1371/journal.pone.0060435.Peer-Reviewed Original ResearchConceptsCrohn's diseaseDisease activityImmune activationDepressive symptomsDepression scoresTrp availabilityΑ treatmentTryptophan availabilityNegative APPsAnti-tumor necrosis factorPast depressive disorderTNF-α treatmentSymptoms of depressionQuality of lifeCD patientsIBDQ scoreImmune markersComorbid depressionDepressive disorderNecrosis factorInflammatory reactionPatientsSymptomsDiseaseTreatment
2012
Plasma concentrations of soluble cytokine receptors in euthymic bipolar patients with and without subsyndromal symptoms
Cetin T, Guloksuz S, Cetin E, Gazioglu S, Deniz G, Oral E, van Os J. Plasma concentrations of soluble cytokine receptors in euthymic bipolar patients with and without subsyndromal symptoms. BMC Psychiatry 2012, 12: 158. PMID: 23013558, PMCID: PMC3532147, DOI: 10.1186/1471-244x-12-158.Peer-Reviewed Original ResearchChoice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence?
Jauhar S, Guloksuz S, Andlauer O, Lydall G, Marques J, Mendonca L, Dumitrescu I, Roventa C, De Vriendt N, Van Zanten J, Riese F, Nwachukwu I, Nawka A, Psaras R, Masson N, Krishnadas R, Volpe U, European Federation of Psychiatric Trainees' Research Group. Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence? BMC Psychiatry 2012, 12: 27. PMID: 22463055, PMCID: PMC3337226, DOI: 10.1186/1471-244x-12-27.Peer-Reviewed Original ResearchConceptsSecond-generation antipsychoticsCognitive behavioral therapyUse of SGAsSecond-generation antipsychotic medicationsKnowledge of trialQuestionnaire-based studyAntipsychotic medicationAntipsychotic treatmentTreatment choicePatientsBehavioral therapyForms of psychotherapyOwn treatmentAntipsychoticsTreatmentPsychosisTrialsPsychiatry traineesEfficacyTrainees
2011
P03-79 - How do european psychiatry trainees prescribe when treating depression, and what influences decision-making? (Survey of the European Federation of Psychiatric Trainees Research Group)
Jauhar S, Guloksuz S, Marques J, Nawka A, Roventa C, Psaras R, Andlauer O, Lydall G, De Vriendt N, Mendonca L, Van Zanten J, Dumiterscu I, Nwachukwu I, Riese F, Group E. P03-79 - How do european psychiatry trainees prescribe when treating depression, and what influences decision-making? (Survey of the European Federation of Psychiatric Trainees Research Group). European Psychiatry 2011, 26: 1248. DOI: 10.1016/s0924-9338(11)72953-4.Peer-Reviewed Original ResearchSide effect profileClinical practiceChoice of antidepressantSevere depressive episodeAntidepressant medicationDepressive episodeTreatment choiceResponse rateAntidepressantsSimilar antidepressantsSubsequent guidelinesPatientsEvidence baseMinimum response rateGuideline suggestionsRecent evidenceMedicationsEuropean traineesPsychiatry traineesEfficacyLittle evidenceSample sizeTraineesFactorsRecent literatureP01-239 - The effects of childhood trauma on psychotic symptoms in bipolar disorder
Ozkose M, Guclu O, Guloksuz S, Karaca O, Yildirim B, Ince B, Erkmen H. P01-239 - The effects of childhood trauma on psychotic symptoms in bipolar disorder. European Psychiatry 2011, 26: 240. DOI: 10.1016/s0924-9338(11)71950-2.Peer-Reviewed Original ResearchYoung Mania Rating ScaleMontgomery-Asperg Depression Rating ScalePsychotic episodeBipolar patientsBipolar disorderChildhood Trauma QuestionnaireChildhood traumaPsychotic symptomsRating ScaleDuration of illnessSexual abuse scoresDepression Rating ScaleMania Rating ScaleStandard treatment planTerms of ageAbuse scoresDSM-IV-TRBakirkoy ResearchInpatient unitPatientsTraining hospitalsPhysical abuse scoresPositive symptomsTherapeutic interventionsTreatment plan
2010
Cytokine levels in euthymic bipolar patients
Guloksuz S, Cetin E, Cetin T, Deniz G, Oral E, Nutt D. Cytokine levels in euthymic bipolar patients. Journal Of Affective Disorders 2010, 126: 458-462. PMID: 20537397, DOI: 10.1016/j.jad.2010.04.027.Peer-Reviewed Original ResearchConceptsEuthymic bipolar patientsBipolar patientsCytokine levelsHealthy controlsBipolar disorderDepressive episodeLithium monotherapyIL-10 levelsIL-4 levelsSerum cytokine levelsPro-inflammatory stateEffects of medicationNeuro-immune modulationTerms of agePatients 16Cytokine profileCytokine productionPresent studyIL-2IL-4IL-5Healthy volunteersPsychiatric disordersPatientsFlow cytometry